Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma.

Lilis I, Ntaliarda G, Papaleonidopoulos V, Giotopoulou GA, Oplopoiou M, Marazioti A, Spella M, Marwitz S, Goldmann T, Bravou V, Giopanou I, Stathopoulos GT.

Oncoimmunology. 2019 Apr 11;8(7):1593802. doi: 10.1080/2162402X.2019.1593802. eCollection 2019.

2.

Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma.

Kerdidani D, Chouvardas P, Arjo AR, Giopanou I, Ntaliarda G, Guo YA, Tsikitis M, Kazamias G, Potaris K, Stathopoulos GT, Zakynthinos S, Kalomenidis I, Soumelis V, Kollias G, Tsoumakidou M.

Nat Commun. 2019 Mar 29;10(1):1405. doi: 10.1038/s41467-019-09370-z.

3.

Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors.

Klotz LV, Courty Y, Lindner M, Petit-Courty A, Stowasser A, Koch I, Eichhorn ME, Lilis I, Morresi-Hauf A, Arendt KAM, Pepe M, Giopanou I, Ntaliarda G, Behrend SJ, Oplopoiou M, Gissot V, Guyetant S, Marchand-Adam S, Behr J, Kaiser JC, Hatz RA, Lamort AS, Stathopoulos GT.

Cancer Med. 2019 Apr;8(4):1486-1499. doi: 10.1002/cam4.2031. Epub 2019 Feb 25.

4.

NRAS destines tumor cells to the lungs.

Giannou AD, Marazioti A, Kanellakis NI, Giopanou I, Lilis I, Zazara DE, Ntaliarda G, Kati D, Armenis V, Giotopoulou GA, Krontira AC, Lianou M, Agalioti T, Vreka M, Papageorgopoulou M, Fouzas S, Kardamakis D, Psallidas I, Spella M, Stathopoulos GT.

EMBO Mol Med. 2017 May;9(5):672-686. doi: 10.15252/emmm.201606978.

Supplemental Content

Loading ...
Support Center